Utah-based Clene Lands a $45.1 Million, 4-Year NIH Grant that Expands Access to its ALS Drug Candidate: CNM-Au8®
Awarded in partnership with Columbia University and Synapticure, this grant provides a pathway for patients with Lou Gehrig's Disease to pursue "Compassionate Use" participation in a new Expanded Access Protocol (EAP) treatment program with Clene as amyotrophic lateral sclerosis (ALS) sufferers.
In major drug discovery news